annual general meeting review, page-30

As I respect your opinion Stoney, I took the time to revisit the presentation to see if I had missed something.

On review, my opinion remains the same.

The presentation was very backward looking.

AE has done a better job at selling the next 12-36 months for cardiocel than the presentation did.

For a company that developed a product which is clearly superior to all others available on the market the presentation did a poor job of selling its prospects.

My dissapointment is not in their business model, or their achievements over the last twelve months, or how well they have achieved their milestones in the past, but how few were set for the future.

A whole 70 words were used in the year ahead section.

It was not unreasonable to expect market penetration expectations or sales targets for cardiocel and for infusion products.

Ahz is less of a speculative co now and I (and evidently the market) expected the presentation to share holders to reflect this.